Identifying molecular determinants of response to oxaliplatin in metastatic bowel cancer
Dr S McDade
Dr P Dunne
Prof D Longley
No more applications being accepted
Funded PhD Project (UK Students Only)
The majority of late-stage bowel cancer (BC) patients are treated with a cocktail of drugs including oxaliplatin, which is associated with significant side-effect of chronic peripheral neuropathy in approximately 50% of patients. Currently there is no effective way to identify patients who will benefit from addition of Oxaliplatin to their treatment; there is therefore an urgent unmet clinical need to limit unnecessary exposure of patients to the chronic, potentially life-altering side-effects of this agent. Dealing with the side-effects and the cost of the agent also imposes a significant financial burden on struggling healthcare systems.
Our research using cutting-edge genomic analyses at Queen’s University Belfast and as part of the S:CORT (Stratification in COloRectal cancer: from biology to Treatment prediction) consortium has begun to unravel which “sub-types” of BC benefit most from standard chemotherapy treatments. This has identified a key role for a gene called “p53” in determining response to chemotherapy.
This PhD studentship will exploit our wealth of existing patient and lab-based chemotherapy response data to identify which patients are most likely to respond to oxaliplatin-based chemotherapy and enable patients who will not benefit to avail of alternative therapies. The ultimate goals are translation of these findings into the clinic.
*FUNDING CONFIRMED – Bowel and Cancer Research Grant*
Eligibility for both fees and maintenance (2020/21 TBC)
When applying, please choose 'MEDICINE' as your subject area/School.
Please visit the School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, website for further details about the Centre: